Trial Enrolls Hundreds in Push to Stop Congo's Deadliest Ebola Outbreak

October 3, 2026 - 05:41

More than 250 participants have been enrolled in a trial for a drug that could stop them from contracting Ebola in Congo. The study aims to test whether an experimental vaccine or treatment can protect people who have been exposed to the virus before they develop symptoms.

Health workers in the affected region have faced significant challenges. The outbreak has spread across multiple provinces, and insecurity in some areas has made it difficult for medical teams to reach patients and their contacts. Community mistrust, fueled by years of conflict and misinformation, has also slowed response efforts.

The trial focuses on ring vaccination, a strategy that involves identifying and immunizing people who have come into contact with confirmed cases. This approach was used during earlier outbreaks in West Africa and eastern Congo, where it helped contain the virus. Researchers hope the new drug will offer longer-lasting protection and be easier to administer in remote settings.

If the trial succeeds, it could become a critical tool for halting future outbreaks before they spiral out of control. Health officials say the results will also inform global stockpile decisions and vaccination guidelines for high-risk populations.

The current outbreak has already claimed hundreds of lives, making it one of the deadliest on record in the country. Medical teams continue to monitor participants for side effects and immune responses. Full results are expected in the coming months.